RB1 and lung neuroendocrine neoplasm: In contrast, KMT2D mutations are less related to TP53 and RB1; it has instead been linked to a longer survival in patients with lung neuroendocrine tumors [30] despite that it has also been shown not to be involved in reducing survival of NSCLC patients [31].